SNY : Summary for Sanofi American Depositary Shar - Yahoo Finance

U.S. Markets closed

Sanofi (SNY)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
45.27-0.08 (-0.18%)
At close: 4:02PM EDT

45.28 0.01 (0.02%)
After hours: 4:34PM EDT

People also watch
NVSGSKAZNLLYNVO
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close45.35
Open45.24
Bid0.00 x
Ask0.00 x
Day's Range45.22 - 45.47
52 Week Range36.81 - 45.95
Volume1,608,545
Avg. Volume1,736,660
Market Cap111.88B
Beta0.76
PE Ratio (TTM)23.40
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.58 (3.48%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals9 hours ago

    Sanofi Genzyme files preemptive legal strike to protect eczema drug

    Sanofi-Genzyme, which expects to soon win approval for an eczema drug, has filed a federal lawsuit that seeks to preempt a possible patent challenge by Amgen. The Cambridge-based firm, a unit of French pharmaceutical giant Sanofi SA (SNY), filed a suit in Boston federal court along with its partner Regeneron Pharmaceuticals (REGN). The complaint asks a judge to rule that the drug does not infringe a patent held by Amgen (AMGN).

  • Regeneron & Sanofi's Atopic Dermatitis Drug Gets FDA Nod
    Zacks11 hours ago

    Regeneron & Sanofi's Atopic Dermatitis Drug Gets FDA Nod

    Regeneron Pharmaceuticals, Inc. (REGN) and its partner Sanofi (SNY) announced that the FDA has approved the Dupixent (dupilumab) Injection, for the treatment of adults with moderate-to-severe atopic dermatitis (AD).

  • Investopedia11 hours ago

    Regeneron & Sanofi's Atopic Dermatitis Drug Gets FDA Nod

    Regeneron Pharmaceuticals, Inc.  REGN and its partner Sanofi SNY announced that the FDA has approved the Dupixent (dupilumab) Injection, for the treatment of adults with moderate-to-severe atopic dermatitis ...